Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound

100Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

Abstract

Congenital deficiency of the mitochondrial respiratory chain complex I (CI) is a common defect of oxidative phosphorylation (OXPHOS). Despite major advances in the biochemical and molecular diagnostics and the deciphering of CI structure, function assembly and pathomechanism, there is currently no satisfactory cure for patients with mitochondrial complex I defects. Small molecules provide one feasible therapeutic option, however their use has not been systematically evaluated using a standardized experimental system. In order to evaluate potentially therapeutic compounds, we set up a relatively simple system measuring different parameters using only a small amount of patient's fibroblasts, in glucose free medium, where growth is highly OXPOS dependent. Ten different compounds were screened using fibroblasts derived from seven CI patients, harboring different mutations. 5-Aminoimidazole-4-carboxamide ribotide (AICAR) was found to be the most beneficial compound improving growth and ATP content while decreasing ROS production. AICAR also increased mitochondrial biogenesis without altering mitochondrial membrane potential (Δψ). Fluorescence microscopy data supported increased mitochondrial biogenesis and activation of the AMP activated protein kinase (AMPK). Other compounds such as; bezafibrate and oltipraz were rated as favorable while polyphenolic phytochemicals (resverastrol, grape seed extract, genistein and epigallocatechin gallate) were found not significant or detrimental. Although the results have to be verified by more thorough investigation of additional OXPHOS parameters, preliminary rapid screening of potential therapeutic compounds in individual patient's fibroblasts could direct and advance personalized medical treatment. © 2011 Golubitsky et al.

References Powered by Scopus

Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α

3624Citations
N/AReaders
Get full text

AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity

2735Citations
N/AReaders
Get full text

A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis

1110Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mitochondria: In sickness and in health

2547Citations
N/AReaders
Get full text

Mitochondrial Diseases: Hope for the Future

276Citations
N/AReaders
Get full text

Complex I deficiency: Clinical features, biochemistry and molecular genetics

260Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Golubitzky, A., Dan, P., Weissman, S., Link, G., Wikstrom, J. D., & Saada, A. (2011). Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveals AICAR as the most beneficial compound. PLoS ONE, 6(10). https://doi.org/10.1371/journal.pone.0026883

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 40

61%

Researcher 17

26%

Professor / Associate Prof. 8

12%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 28

42%

Biochemistry, Genetics and Molecular Bi... 20

30%

Medicine and Dentistry 13

20%

Pharmacology, Toxicology and Pharmaceut... 5

8%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free